Abstract
Alemtuzumab is a lymphocyte ablative agent that may cause susceptibility to severe opportunistic infections similar to those seen in AIDS. Pathogen-specific immune reconstitution syndromes can complicate antiretroviral therapy and immune recovery in HIV-infected patients. We present the first reported case of immune reconstitution syndrome associated with T lymphocyte recovery after alemtuzumab therapy.
MeSH terms
-
Alemtuzumab
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm / adverse effects*
-
Antineoplastic Agents / adverse effects*
-
Cryptococcus neoformans / immunology*
-
Cryptococcus neoformans / pathogenicity
-
Humans
-
Immune System Diseases / immunology*
-
Immune System Diseases / microbiology
-
Leukemia, Prolymphocytic / complications
-
Leukemia, Prolymphocytic / drug therapy
-
Leukemia, Prolymphocytic / immunology*
-
Leukemia, T-Cell / complications
-
Leukemia, T-Cell / drug therapy
-
Leukemia, T-Cell / immunology*
-
Male
-
Middle Aged
-
Salvage Therapy / adverse effects
-
Syndrome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Antineoplastic Agents
-
Alemtuzumab